نتایج جستجو برای: hepatic dysfunction

تعداد نتایج: 246475  

Journal: :research in molecular medicine 0
kasra ghanaat faculty of medicine, mazandaran university of medical sciences, sari, iran. amir valizadeh-dizajeykan faculty of medicine, mazandaran university of medical sciences, sari, iran. majid malekzadeh-shafaroudi department of anatomy, mazandaran university of medical sciences, sari, iran. abbas khonakdar-tarsi department of biochemistry and genetics, faculty of medicine, mazandaran university of medical sciences, sari, iran.

background: hepatic ischemia/reperfusion injury (i/ri) is a multifactorial pathophysiologic process which can lead to liver damage and dysfunction. this study examined the protective effect of dexamethasone on the gene expression of endothelial nitric oxide synthase (enos) and endothelin-1 (et-1) and on the liver tissue damage during warm hepatic i/r. methods: a total of 32 male wistar rats was...

2014
Dong-Gyu Park Ji Soo Kim Sun-Uk Lee Tae-Sung Lim Young Moon

Sustained downgaze mostly occurs in association with lesions affecting the dorsal midbrain. We report sustained downgaze in a patient with hepatic encephalopathy. The sustained downgaze existed for seven more days after she regained her consciousness. The persistent downgaze even after regaining full consciousness indicates localized pretectal dysfunction rather than diffuse encephalopathy as t...

2009
Marc G. Jeschke Gerd G. Gauglitz Juquan Song Gabriela A. Kulp Celeste C. Finnerty Robert A. Cox José M. Barral David N. Herndon Darren Boehning

A hallmark of the disease state following severe burn injury is decreased liver function, which results in gross metabolic derangements that compromise patient survival. The underlying mechanisms leading to hepatocyte dysfunction after burn are essentially unknown. The aim of the present study was to determine the underlying mechanisms leading to hepatocyte dysfunction and apoptosis after burn....

2012
Marcos Pasarín Vincenzo La Mura Jorge Gracia-Sancho Héctor García-Calderó Aina Rodríguez-Vilarrupla Juan Carlos García-Pagán Jaime Bosch Juan G. Abraldes

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome. Most morbidity associated with the metabolic syndrome is related to vascular complications, in which endothelial dysfunction is a major pathogenic factor. However, whether NAFLD is associated with endothelial dysfunction within the hepatic vasculature is unknown. The aims of this study were to expl...

2010
Tetsuhiro Yoshino Daisuke Kawano Takeo Azuhata Tsukasa Kuwana Rikimaru Kogawa Atsushi Sakurai Katsuhisa Tanjoh Tatsuo Yanagawa

A 56-year-old woman with Graves' disease presented with the complaints of diarrhea and palpitations. Physical examination and laboratory data revealed hypothermia and signs of mild hyperthyroidism, heart failure, hepatic dysfunction with jaundice, hypoglycemia, and lactic acidosis. The patient was diagnosed as having developed the complication of thyroid storm in the absence of marked elevation...

2016
Zhan Liu Peng Li Zhi-Hong Zhao Yu Zhang Zhi-Min Ma Shuang-Xi Wang

Backgrounds. VitB6 deficiency has been associated with a number of adverse health effects. However, the effects of VitB6 in metabolic syndrome are poorly understood. Methods. VitB6 (50 mg/kg/day) was given to Apoe (-/-) mice with hkdigh-fat diet (HFD) for 8 weeks. Endothelial dysfunction, insulin resistance, and hepatic lipid contents were determined. Results. VitB6 administration remarkably in...

Journal: :Endocrine journal 2008
Yutaka Takahashi Keiji Iida Ryoko Takeno Riko Kitazawa Sohei Kitazawa Hidetsuna Kitamura Yoshio Fujioka Hiroyuki Yamada Fumio Kanda Shigeo Ohta Kiyomi Nishimaki Masayo Fujimoto Takeshi Kondo Genzo Iguchi Kentaro Takahashi Hidesuke Kaji Yasuhiko Okimura Kazuo Chihara

Mitochondrial diabetes is characterized by diabetes and hearing loss in maternal transmission with a heteroplasmic A3243G mutation in the mitochondrial gene. In patients with the mutation, it has been reported that hepatic involvement is rarely observed. We demonstrated a case of hypertrophic cardiomyopathy and hepatic failure with mitochondrial diabetes. To clarify the pathogenesis we analyzed...

Journal: :Oncology 2005
John W Eklund Steve Trifilio Mary F Mulcahy

Advanced cancer in the setting of liver dysfunction poses a dilemma for physicians, as many cancer chemotherapeutic agents undergo hepatic metabolism. Most cytotoxic drugs have a narrow therapeutic index, and the administration of chemotherapy to patients with liver impairment results in complicated safety issues. We present a concise review of cancer chemotherapy dosing in the setting of liver...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 1999
C Twelves R Glynne-Jones J Cassidy J Schüller T Goggin B Roos L Banken M Utoh E Weidekamm B Reigner

Capecitabine (Xeloda) is a rationally designed oral, tumor-selective fluoropyrimidine carbamate aimed at preferential conversion to 5-fluorouracil (5-FU) within the tumor. Because capecitabine is extensively metabolized by the liver, it is important to establish whether liver dysfunction altered the pharmacokinetics of capecitabine and its metabolites. This was investigated in 14 cancer patient...

Journal: :Transplantation proceedings 1990
A B Jain R Venkataramanan E Cadoff J J Fung S Todo A Krajack T E Starzl

I N initial clinical trials of organ transplanta.tion, F~. 5~ has shown remarkable immunosuppressive activity. The drug is very lipophilic. metabolized in the liver, and predominantly eliminated through the bile. 2 Hepatic dysfunction was expected to alter the pharmacokinetics of FK 506. Hepatic dysfunction is also known to alter the absorption of lipid soluble drugs. 3 This is related to the l...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید